Phase 2
Active, not recruiting
1,005
2026-07
Industry sponsor intelligence
RegeneronClinical Pipeline.
Lead-sponsor view of Regeneron's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 4
- Recruiting
- 1
- Active
- 1
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 327
Pipeline overview
Programs by phase and activity.
Velocity
Regeneron trials by start year
Study start year · indexed snapshot
Development
Trials by phase
4phase labels
Early Phase 10
Phase 10
Phase 23
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Metreleptin → | 1 | 0 | 0 | 1 | 0 | 0 |
| Nesiritide → | 1 | 0 | 1 | 0 | 0 | 0 |
| Semaglutide → | 1 | 0 | 1 | 0 | 0 | 1 |
| Tirzepatide → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Phase 2
Recruiting
204
2026-06
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Regeneron · Generalized Lipodystrophy
Phase 3
Completed
9
2026-07
Search sponsor records
All Regeneron studies.
This page groups studies where Regeneron is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
4 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06548100A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)Jul 29, 2026NCT06299098A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationJul 21, 2026NCT07527910A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDJun 26, 2026NCT06237309REGN5381 in Adult Participants With Heart Failure With Reduced Ejection FractionJan 14, 2026